Please assess the completion status of the following clinical trial:

Trial Title: Study of FORTEO Use in Subjects in the Community Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women who are judged by the study physician to be suitable for FORTEO therapy. The FORTEO product labeling specifies those individuals diagnosed with osteoporosis who are considered to be at high risk for fracture~Exclusion Criteria:~* Subjects who have an increased baseline risk for osteosarcoma. These include Paget's disease of bone, pediatric populations and young adult patients with open epiphyses, prior external beam or implant radiation therapy involving the skeleton~* Subjects who have administered FORTEO or PTH therapy for more than two weeks directly before study entry~* Subjects who have completed a course of FORTEO or PTH therapy of at least 18 months duration before study entry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FORTEO (teriparatide)-treated (Type: None): FORTEO-treated

Based on this trial design, predict the completion outcome and termination type (if applicable).